Savolitinib and durvalumab for metastatic papillary kidney cancer
In a phase 2 clinical trial, patients with metastatic papillary [...]
Adjuvant nivolumab plus ipilimumab for localised kidney cancer
In this randomised phase 3 trial, the effectiveness and safety [...]
Fat loss may result in worse outcomes for patients treated with immunotherapy for metastatic kidney cancer
A recent study presented at the Annual Congress of the [...]
How time of day of immunotherapy infusion affects kidney cancer outcomes
Recent studies have suggested that the time of day when [...]
Benefits persist for lenvatinib plus pembrolizumab in advanced kidney cancer
Lenvatinib plus pembrolizumab has already been shown to improve survival [...]
TKI treatment breaks may not affect outcomes in kidney cancer
The results of the phase 2/3 STAR trial were published [...]
ASCO GU 20023: Cabozantinib as a second-line treatment for patients with advanced kidney cancer
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: A triple combination for previously untreated kidney cancer patients
At the American Society of Clinical Oncology Genitourinary Cancers Conference [...]
ASCO GU 2023: Treatment-free survival for advanced kidney cancer patients on nivolumab and salvage nivolumab/ipilimumab
In this study presented at the American Society of Clinical [...]
Savolitinib plus durvalumab for papillary kidney cancer
In a recent study published in the Journal of Clinical [...]
